Pancragen: The Complete Guide

Pancragen is the synthetic Khavinson tetrapeptide Lys-Glu-Asp-Trp, typically supplied as the C-terminal amide form H-Lys-Glu-Asp-Trp-NH2 (KEDW-NH2). Four amino acids: lysine-glutamate-aspartate-tryptophan.

Identity verification (NLM + PubMed):

• NLM MeSH Supplementary Concept “lysyl-glutamyl-aspartyl-tryptophanamide” maps directly to the trade name “Pancragen.”
• PMID 25946840 explicitly states: “Pancragen (tetrapeptide Lys-Glu-Asp-Trp) on endocrine function of the pancreas of non-human primates, female rhesus monkeys.”
• PMID 18642713 explicitly states: “The effects of tetrapeptide pancragen (Lys-Glu-Asp-Trp-NH2) on blood glucose level…”
• PMID 16671579 (founding paper, 2005): KEDWa was synthesized as an analog of a four-residue motif found across natural insulinotropic polypeptides, designed to be protected from gastrointestinal proteinases.

Pancragen is part of the Khavinson short-peptide family

Synthesized at the St. Petersburg Institute of Bioregulation and Gerontology (SPIBG). Sister peptides include Cartalax (AED), Prostamax (KEDP), Testagen (KEDG), Epitalon (AEDG), and Pinealon (EDR). Each is positioned as a tissue-specific bioregulator.

Parent extract: Suprefort (A-1)

Khavinson positions Pancragen as the synthetic short-peptide analog of an “insulinotropic-polypeptide motif.” The parent Suprefort (A-1) is a bovine-pancreas polypeptide-complex extract (oral capsule, Cytomax line, NPCRiZ retail). Critical regulatory note: both synthetic Pancragen and Suprefort are sold in Russia as биологически активная добавка (БАД, biologically active food additive) — neither is a registered Russian pharmaceutical. This is a different regulatory profile from Prostamax/Prostatilen (where the prostate parent extract IS a registered Russian pharma). Suprefort has zero PubMed-indexed primary research on the extract itself.

Pancragen is NOT:

• Not insulin. It does not bind the insulin receptor. It is not a hormone replacement.
• Not a GLP-1 receptor agonist. Not a structural analog of GLP-1. The “insulinotropic” framing in the founding paper refers to a sequence-motif mimetic shared across multiple insulinotropic polypeptides, not GLP-1R binding. This is the most consequential disambiguation point — Pancragen is not an alternative to semaglutide, tirzepatide, or retatrutide.
• Not a sulfonylurea (different mechanism — PMID 28509500 explicitly compared pancragen vs. glimepiride and described their effects as mechanistically distinct).
• Not a DPP-4 inhibitor, not metformin, not an SGLT2 inhibitor.

Regulatory status:

• FDA (US): not approved. No NDA, no IND. Not on the 503A bulks list, not on the 503B essentially-copies list.
• EMA (EU): not approved.
• Russia: Russian БАД tier (synthetic Pancragen and Suprefort both). Not a registered Russian pharmaceutical.
• WADA 2026: not on the 2026 Prohibited List by name. As an unapproved investigational substance, S0 (“non-approved substances”) is the catch-all argument. Athletes should consult their governing body before use.

Khavinson framework: short peptides penetrate the cell membrane and the nuclear envelope, bind specific DNA promoter regions and histone N-terminal tails, and modulate tissue-specific gene expression. This framework is computationally docked, not crystal-structure validated. No published X-ray or NMR structure of KEDW bound to DNA exists.

Direct findings on KEDW (verified PMIDs):

1. Insulin biosynthesis restoration (PMID 16671579, founding paper)

KEDWa “partially restored insulin synthesis” in alloxan-diabetic rats; sugar-curve slope similar to normal animals. Proposed mechanism: KEDWa “activates the preproinsulin gene promoter site via complementary interactions with the ggcagg and cctgcc nucleotide sequences” on the leading strand of double-stranded DNA.

2. β-cell differentiation factor upregulation (PMID 23486591)

Pancragen upregulates Pdx1 and Ptfla (acinar) and Pdx1, Pax4, Pax6, Foxa2, Nkx2.2 (islet) in young and aged human pancreatic cell cultures. These are canonical β-cell-fate transcription factors.

3. DNA-binding via major groove (PMID 24770759, computational)

KEDW docks preferentially to the GGCAG sequence in the DNA major groove; major-groove binding is sequence-specific while minor-groove binding is more permissive.

4. Promoter-methylation modulation (PMID 25761685)

KEDW affects DNA-methylation patterns of PDX1, PAX6, NGN3 promoter regions in human pancreatic cell cultures, with promoter-methylation changes correlating with expression changes for those three genes.

5. Histone-tail binding (PMID 23581987)

KEDW binds wheat histones H1, H2B, H3, H4 with site-specific Stern-Volmer constants (Vanyushin lab; wheat histones rather than human reflects the lab’s plant-genetics background).

6. Tissue-specific differentiation marker upregulation (PMID 22808515)

KEDW upregulates CXCL12 + Hoxa3 in human embryonic pancreatic cells. Effect more pronounced in aged cultures — the Khavinson-framework geroprotector signature.

7. Capillary endothelial-protective effect (PMID 18642713)

IM pancragen normalized mesenteric-capillary adhesion in STZ-diabetic rats but did not modify capillary permeability. Oral pancragen produced “a pronounced hypoglycemic effect during treatment.”

8. Pancreatic explant outgrowth at 0.05 ng/mL (PMID 17152728)

Sub-nanogram tissue-effective concentration in young and aged rat pancreas organotypic culture.

9. Pro-proliferative + anti-apoptotic profile in aged pancreatic cells (PMID 23734516)

KEDW-NH2 upregulates MMP2, MMP9, serotonin, CD79α, Mcl1, PCNA, Ki67; downregulates p53. This is the audit-critical mechanistic finding — see the Cancer concern section below.

Net mechanism read:

KEDW is a putative DNA-binding bioregulator: in vitro and in animal models it docks to GGCAG / acct sequences, binds histone tails, drives expression of canonical β-cell-fate transcription factors, normalizes glucose tolerance and insulin / C-peptide dynamics in aging and diabetes models, and shifts the cell-cycle / apoptosis balance toward proliferation. All mechanism claims are computationally supported, not biophysically validated.

Banner: all evidence is preclinical or single-cohort Russian observational. No Western RCT exists. No Phase 1/2/3 trial. No clinicaltrials.gov entries.

Claim	Source	Evidence Tier
Restoration of insulin synthesis (alloxan-diabetic rats)	PMID 16671579	Preclinical animal model
β-cell differentiation factor upregulation (Pdx1, Pax4, Pax6, Foxa2, Nkx2.2)	PMID 23486591	In vitro human cells
Hypoglycemic effect (oral); capillary endothelial protection (IM)	PMID 18642713	Preclinical (STZ rats)
Pancreatic explant outgrowth at 0.05 ng/mL	PMID 17152728	Organotypic rat culture
Glucose tolerance normalization in old rhesus monkeys	PMIDs 25946840, 28509500	Preclinical primate; n=5–9 per study
Pancragen vs. glimepiride comparison	PMID 28509500	Old rhesus monkeys; n=5 vs. 4; not human
Reduced fasting glucose, OGTT response, plasma insulin, IR index in elderly T2DM	PMID 22448364	Single Russian Korkushko cohort, n=33; methodology underspecified; no Western replication
Stem-cell-engineering β-cell-lineage modulation	PMID 39871657 (review, 2025)	First independent (non-Khavinson, non-Vanyushin) PubMed acknowledgment of KEDW; review-tier, no new data

The single human study (PMID 22448364) — reading limitations:

• Sample size: 33 type-2-DM patients + 30 healthy elderly controls.
• Design not described in the abstract as randomized, blinded, or placebo-controlled.
• Effect sizes not extracted in abstract.
• Dose, duration, route: not specified in the abstract.
• HbA1c, hard glycemic-control endpoints, cardiovascular endpoints, microvascular endpoints: not reported.
• No follow-up paper expanding on this work has been published in the 14 years since.

No human RCT of synthetic Pancragen has been published. The dose ranges below reflect the Russian rhesus-monkey IM dose extrapolated to human weight, plus vendor / community convention. They are not validated clinical protocols.

Animal-anchored reference:

The Goncharova rhesus-monkey trials (PMIDs 25946840, 28509500) used 50 µg/animal/day IM × 10 days in old female rhesus monkeys (5–8 kg body weight). Naive body-weight scaling to a 70-kg human yields ~0.4–0.7 mg/day equivalent; allometric (BSA) scaling gives a smaller equivalent. This scaling is not validated by any human PK study.

Vendor / community convention:

Route	Common Range	Cycle
Subcutaneous injection	100–400 µg/day	10–20 days on, 2–4 cycles per year
Oral capsule (KEDW-NH2 GI-protected per founding paper design)	100–400 µg/day	10–20 days on, 2–4 cycles per year
Intramuscular (Russian primate-trial route)	~50–500 µg/day	10 days on, repeat per year

Suprefort extract (parent, not synthetic Pancragen):

1 capsule (~10 mg natural peptides) twice daily × 30 days; multiple courses per year per vendor literature. Suprefort and synthetic Pancragen are not interchangeable — different molecules, different evidence trails.

Combination with anti-diabetic drugs:

Concurrent use of Pancragen with insulin, sulfonylureas, GLP-1 RAs, or DPP-4 inhibitors is uncharacterized in published research. Theoretical hypoglycemia risk in combination. Physician supervision required for diabetic users on prescription therapy.

Standard short-peptide SC reconstitution. For a typical 5–10 mg lyophilized vial:

• Add 2 mL bacteriostatic water → final concentration 2.5–5 mg/mL (2500–5000 µg/mL).
• On a U-100 insulin syringe, 1 unit = 25–50 µg depending on vial size.
• For a 5 mg vial reconstituted in 2 mL: 1 unit = 25 µg; 100 µg dose = 4 units.
• For a 10 mg vial reconstituted in 2 mL: 1 unit = 50 µg; 100 µg dose = 2 units.

Storage:

• Lyophilized: stable at room temperature short-term; refrigerate for longer storage.
• Reconstituted: refrigerate. Use within 28 days.
• Oral capsule: store dry, room temperature, away from light.

For the full reconstitution protocol, see the Bacteriostatic Water guide.

No PubMed-indexed safety / pharmacovigilance paper on synthetic Pancragen. No FAERS or EudraVigilance entries. No Western pharmacovigilance trail.

Reported tolerability:

• The Goncharova monkey papers (PMIDs 25946840, 28509500) report no adverse events over 10-day IM courses in 5–9 monkeys.
• The Korkushko human-perspective paper (PMID 22448364) does not extract adverse-event data in the abstract.
• Suprefort vendor literature reports “well-tolerated, no contraindications other than individual hypersensitivity” — vendor / БАД-tier safety messaging, not pharmacovigilance.

Theoretical concerns:

• Hypoglycemia in non-diabetic users. Mechanism: β-cell support + insulin-sensitivity improvement. Monitor blood glucose if used by individuals without diabetes.
• Hypoglycemia in combination with insulin / sulfonylureas / GLP-1 RAs. No interaction studies; proceed only with physician supervision.

The “well-tolerated in Russian use” framing should not be read as a safety-equivalence claim — Western pharmacovigilance does not exist for this molecule.

The pancreas is one of the highest-stakes target tissues in the Khavinson family for two reasons:

1. Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal common cancers (5-year survival ~10–13%). Any compound marketed as “supporting pancreatic cell function” warrants a defensible position on whether it could accelerate occult PDAC.
2. Insulinoma is a real (if rare) β-cell tumor. A peptide that drives β-cell-fate transcription factors plus PCNA / Ki67 / Mcl1 is mechanistically aligned with β-cell proliferation pressure.

The PMID 23734516 finding:

Khavinson group, Adv Gerontol 2012. Verbatim from the abstract: “the studied tetrapeptide increases the expression of matrix metalloproteinase MMP2, MMP9, serotonin, glycoprotein CD79alpha, antiapoptotic protein Mcl1, proliferation markers PCNA and Ki67 and decreases the expression of proapoptotic protein p53 in aged pancreatic cell cultures.”

The Khavinson interpretation: “restoration of youthful tissue dynamics.” An oncology-conservative interpretation: “elevated proliferation pressure with anti-apoptotic and matrix-degrading shifts.” Both readings are mechanistically tenable. The MMP2 / MMP9 upregulation is closely aligned with the PDAC stromal-invasion gain-of-function pattern.

What hasn’t been tested:

• KEDW has not been tested directly on pancreatic cancer cell lines (PANC-1, MIA PaCa-2, BxPC-3, Capan-1, AsPC-1).
• KEDW has not been tested on insulinoma cell lines (RIN-m5F, INS-1, MIN6).
• KEDW has not been tested in xenograft or genetically-engineered mouse models of PDAC (KPC, KC, Pdx1-Cre;LSL-KrasG12D).

The cancer question is mechanistically flagged but not directly addressed in indexed literature.

Practical contraindications (see Contraindications section):

Active or prior PDAC, insulinoma, or pancreatic neuroendocrine tumor — absolute contraindication. New-onset diabetes within 36 months in adults >50 with weight loss or abdominal symptoms — PDAC workup before consideration. Long-standing T2DM with new GI symptoms — gastroenterologist consult.

• Pregnancy / breastfeeding — no safety data; avoid.
• Type-1 diabetes (insulin-dependent). Pancragen is not a substitute for insulin. Khavinson preclinical literature shows β-cell support and β-cell-fate-factor upregulation, not de novo β-cell regeneration in autoimmune-destroyed islets. Do not replace insulin therapy.
• Active or prior pancreatic ductal adenocarcinoma (PDAC) — absolute contraindication.
• Active or prior insulinoma / pancreatic neuroendocrine tumor (PNET) — absolute contraindication. The β-cell-fate factor profile (Pdx1, Pax4, Pax6, Foxa2, Nkx2.2 + Mcl1, PCNA, Ki67) is the most directly relevant mechanism for PNET acceleration in any Khavinson peptide.
• Personal or family history of MEN1, MEN2, VHL, or NF1 — strong caution (elevated baseline PNET risk). Specialist sign-off recommended.
• New-onset diabetes within 36 months in adults >50 with weight loss or new abdominal symptoms — workup for occult PDAC before considering Pancragen (per ADA / AGA new-onset-diabetes-as-paraneoplastic guidance).
• Long-standing type-2 DM with new GI symptoms — gastroenterologist consult.
• Known IPMN (intraductal papillary mucinous neoplasm) or other pancreatic cystic lesion — caution; gastroenterologist sign-off.
• Concurrent insulin / sulfonylureas / GLP-1 RA / DPP-4 inhibitor — theoretical hypoglycemia risk; physician supervision required.
• History of cancer (per Khavinson-family Cartalax / Prostamax precaution) — the PCNA ↑ / p53 ↓ / Mcl1 ↑ profile is pro-proliferative and anti-apoptotic.
• Athletes subject to anti-doping testing — do not use without consulting your governing body. WADA S0 (non-approved substances) is the catch-all.

Three commonly-confused entities. They are not the same thing.

1. Pancragen = synthetic Khavinson tetrapeptide Lys-Glu-Asp-Trp (KEDW).

NLM MeSH “lysyl-glutamyl-aspartyl-tryptophanamide.” Approximately 10 PubMed-indexed Khavinson-group preclinical papers, anchored on β-cell / glucose-tolerance biology. This guide.

2. Suprefort (A-1) = bovine-pancreas polypeptide-complex extract.

Oral capsule, sold as Russian БАД, Cytomax line under SPIBG patent. The parent extract from which Khavinson positions Pancragen as the synthetic short-peptide mimetic. Zero PubMed-indexed primary research on Suprefort itself. This is a different (worse) parent-extract evidence profile than Prostamax has.

3. Adamax = Ac-Met-Glu-His-Phe-Pro-Gly-Pro-AG-NH2.

An entirely different molecule — N-acetyl Semax with an adamantyl-AG cap from P21. Vendor copy occasionally attaches the trade name “Adamax” to the KEDW sequence. That is a misidentification. Adamax has zero PubMed-indexed primary literature; KEDW belongs to Pancragen. See the Adamax guide for the full disambiguation.

Summary table:

Name	Sequence / Composition	Family	Target	PubMed papers
Pancragen	KEDW (Lys-Glu-Asp-Trp)	Khavinson short-peptide	Endocrine pancreas / β-cells	~10
Suprefort (A-1)	Bovine-pancreas polypeptide complex	Khavinson Cytomax extract	Pancreas (whole-tissue)	0
Adamax	Ac-MEHFPGP-AG-NH2	Semax / P21 hybrid	Cognitive / nootropic	0